Follicular lymphoma (FL) is a low-grade B-cell nomHodgkin's lymphoma (NHLI that frequently transforms into diffuse aggressive NHL. The majority of FLs display a t(14;18) translocation that places the bcl-2 gene into juxtaposition with the Ig heavy-chain (HI gene locus. Morphologically transformed malignant FL cells retain their t(14; 18) translocation and may acquire additional genetic abnormalities. We analyzed serial biopsy specimens from eight patients with FL for secondary alterations of the rearranged bcl-2 gene in the breakpoint and open reading frame (ORF) regions. Two cases of FL showed no histologic alteration in the second biopsy, and six cases of FL showed morphologic transformation to diffuse large-cell lymphoma (DLL) in the second biopsy. Polymerase chain reaction (PCR) amplification, cloning, and sequencing of the junctional region of the hybrid bcl-2/lgH genes showed identical nucleotide sequences in multiple biopsy specimens of FL that did not show morphologic transformation. In patients in whom FL cells underwent morphologic transformation, FL and autologous DLL cells displayed identical bcl-Z/lgH gene nucleotide sequences in five cases and different sequences in one case. In the case for which FL and DLL cells showed different bcl-2ilgH junctional sequences, OLLICULAR LYMPHOMA (FL) is a low-grade B-cell 2 oncogene in sequential biopsy specimens from patients with FL that showed no histologic alterations in subsequent biopsy specimens or underwent morphologic transformation to diffuse large-cell lymphoma (DLL). Our results indicate that DLL cells may represent transformants of the preexisting FL clone, or may emerge from an unrelated B-cell clonotype through a novel and discrete bcl-2 translocation event. They also suggest that somatic mutations of the ORF of the bcl-2 gene are associated with higher-grade NHL cells.
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OLLICULAR LYMPHOMA (FL) is a low-grade B-cell
Intensive structural analysis of the hybrid bcl-2/IgH gene sequence in FLs showed that the translocated bcl-2 gene may undergo further alterations during the natural course of the disease. Somatic mutations of the O W changing the structure of the p26-bcl-2a protein, '8- 2 oncogene in sequential biopsy specimens from patients with FL that showed no histologic alterations in subsequent biopsy specimens or underwent morphologic transformation to diffuse large-cell lymphoma (DLL). Our results indicate that DLL cells may represent transformants of the preexisting FL clone, or may emerge from an unrelated B-cell clonotype through a novel and discrete bcl-2 translocation event. They also suggest that somatic mutations of the ORF of the bcl-2 gene are associated with higher-grade NHL cells.
MATERIALS AND METHODS
Tumor biopsies. Sequential biopsy samples of eight patients with FL observed at Stanford University Medical Center were selected for this study based on availability of frozen tissue for molecular analyses. All lymphoma samples were classified according to the Revised European-American Lymphoma Classification proposed by the International Lymphoma Study Group.' The histology of the first lymph node biopsy in all eight tumor samples was FL, provisional 3938 MATOLCSY ET AL cytologic grade I. In two patients (cases no. 7 and 8), the results of the second biopsy showed no histologic alterations compared with those of the first biopsy. In six patients (cases no. 1 to 6 ) , histology of the second biopsy was classified as DLL ( Table 1) .
Polymerase chain reaction and sequence analysis of the t(14; 18) breakpoints. Genomic DNA preparations extracted from frozen tissue sections using a salting-out procedure were used as templates.2s Polymerase chain reaction (PCR) and sequence analysis were used to characterize the t( 14; 18) translocation in eight paired lymphoma samples. Major breakpoint region (mbr)-or minor cluster region (mu)-specific bcl-2 sense primers in conjunction with a JH antisense primer were used in the PCR, as previously des~ribed.~~~*' PCR DNA products were cloned in pCR 1000 vector using the TA cloning system (Invitrogen Corp, San Diego, CA) following the manufacturer's instructions. DNA sequencing was performed directly from a small-scale plasmid preparation using the Sequenase version 2.0 system (United States Biochemical, Cleveland, OH) according to the manufacturer's instructions. DNA sequences were analyzed using the MacVector version 4.5 (Eastman Kodak Corp, New Haven, CT) software and the GeneBank database.
PCR single-strand conformation polymorphism and sequence analysis of bcl-2 proto-oncogene ORF. PCRs were performed to amplify DNA segments of the bcl-2 ORF corresponding to p26-bcl2a protein. Three pairs of amplification primers were designed for use in separate reactions to achieve PCR amplification of the first gel containing 10% glycerol. Gels were assayed at 4 to 8 W for 14 to 16 hours at room temperature. The gels were fixed in 10% acetic acid and air-dried, and autoradiography was performed at -70°C with an intensifying screen for 6 to 24 hours. To confirm the presence of a mutation, DNAs were amplified under the same conditions a s described for the SSCP, but the radioactive nucleotide was omitted. PCR products were cloned, sequenced, and analyzed as already described.
RESULTS

Molecular characterization of t(14; 18) chromosomal translocations.
DNAs of paired lymphoma samples from eight patients were PCR-amplified using mbr-or mcr-sequence-specific bcl-2 sense primers in conjunction with JHspecific antisense primer. The PCR products were cloned and sequenced. A fusion was demonstrated between the bcl-2 gene and members of the Ig J H exons in all FL and DLL samples, confirming the presence of t( 14; 18) translocations in these tumors. The breakpoint on bcl-2 was within the region referred to as mbr in all cases. The mbr/JH junctional sequences of the hybrid bcl-2flgH gene from initial FL and subsequent FL or DLL B cells were evaluated in parallel.
The results are summarized in Table 1 and illustrated in Fig  1. In the initial FL and corresponding subsequent FL or DLL cells, the bcl-2 gene was juxtaposed with the JH4b gene in one case, the JH6b gene in three cases, and the JH6c gene in four cases. In all but one case, JH sequences showed complete identity with the published germline equivalents. In case no. that of the A polymorphic wild-type control, in cases no. 4 and 8 with that of the G polymorphic wild-type control, and in cases no. 1, 3, and 5 to 7 with that of the N G wild-type controls, suggesting that somatic mutations in the first 221-bp region of the ORF are absent in FL cells. PCR products from DLL samples of cases no. 2, 4, and 6 displayed altered electrophoretic mobility compared with the respective FL cell counterparts, as shown by the results of PCR-SSCP analysis using the primers that span the region from 202 bp to 487 bp of the ORF (Fig 2B) . Altered electrophoretic mobility was detected in the DLL sample of case no. 6. Figure  2C shows the results of PCR-SSCP analysis generated by the primers that span the region from 448 bp to 741 bp of the OW. FL and DLL samples of the eight patients did not exhibit altered electrophoretic mobility compared with unmutated negative controls. 
3939
--" " I^ " " " " DNAs were cloned and sequenced. In each FL and DLL sample. sequences of 20 independent bacterial isolates were analyzed and compared with the germline sequence of the bcl-2 gene ( (Fig 3) . In the DLL sample of case no. 2 , 6 of 20 nucleic acid sequences (clones 2 , 7 to 9, 11, and 14) showed identical mutations at positions -I 1 and 66 (Fig 3A) . In the DLL sample of case no. 4, eight sequences (clones 6, 8, 12 to 16, and 20) contained identical mutations at positions 24, 66, 85, and 137 (Fig 3A) . In the DLL sample of case no. 6, nine sequences (clones 6, 12 to 16, and 18 to 20) contained identical mutations at positions 33, 175, and 176, analyzing the bcl-2 ORF region from -40 bp to 221 bp (Fig 3A) . In the same DNA sample, 10 sequences (clones 1, 2, 5 to 7, 9, 10, and 16 to 18) of the bcl-2 ORF region from 202 bp to 487 bp contained identical mutations at positions 315 and 354 (Fig 3B) . The frequency of identical mutant sequences was 6 to 10 of 20 independent isolates showing amplification of both mutant and wild-type clones. This observation is consistent with our recent PCR approach amplifying both the translocated and wild-type bcl-2 alleles. Furthermore, in the A/G polymorphism patient (case no. 6), the somatic mutations were consistently associated with the G polymorphic allele, suggesting that mutation is associated with only one allele. We presumed that the observed mutations are derived from the translocated bcl-2 gene, because somatic mutations of the bcl-2 gene have not been detected in a large group of normal individuals.28 All 11 somatic mutations were transitions (A --t C or G + T), and 4 of them result in amino acid replacement at codons 29 (E + K), 46 and 59 (P + L), and 106 (R + H) of the p26-bcl-2a protein.
DISCUSSION
Characterization of the clonal relationship between FL and subsequent DLL and identification of molecular mechanisms associated with the morphologic transformation and clinical progression of FL are critical issues in understanding the pathogenesis, diagnosis, and management of these lymphomas. These studies demonstrate that FL and DLL cells may be clonally related or may represent different unrelated clones. They also provide the first evidence that morphologic transformation of FL may be associated with genetic alteration of the p26-bcl-2a oncoprotein.
The present report strengthens previous studies showing that FL and subsequent DLL cells may carry identical t( 14; 18) translocations and junctional bCl-2/J~ gene sequences suggesting a common clonal origin for the two neop l a s m~, " .~~ and it extends them by providing evidence that . . . .^ "_ " " a n n e e n n : g ; ; ; "" . . . "?e",.-a n n * e n 1 1 ... 
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; g ; ; ; r u . . . Recently, cDNAs have been cloned for several novel human genes, revealing a family of bcl-2-related proteins. One of these, termed bax, encodes a 192-amino acid protein with 21 % homology with b~l -2 .~~ An additional bcl-2 homologue is bcl-x, which can generate two proteins through an alternative splicing mechanism: bcl-x-1 (longer form) and bcl-x-s (shorter form)." Gene transfer studies in lymphokine-dependent hematopoietic cells indicate interactions of the bcl-2 protein with itself and other members of the bcl-2 family, including bax, bcl-x-1, and bcl-2-x-s. Bax is envisioned as a cell death (apoptosis) effector, with activity neutralized by binding of bcl-2."' The binding of bcl-x-s to bcl-2 was hypothesized to prevent bcl-2 from interacting with bax, thus leaving bax unopposed in its apoptotic function."' The use of site-specific mutagenesis"' and deletion mutants@ of bcl-2 suggests that bcl-2 homodimerization and heterodimerization with other bcl-2 family members involves interaction between distinct regions within the bcl-2 protein. Whereas BH1 (amino acid 136 to 155) and BH2 (amino acid 187 to 202) domains of bcl-2 are required for heterohybridization with bax:' homodimerization of bcl-2 involves interaction of the amino acid 1 to 81 region between two bcl-2 molecules and/or interaction of amino acid 1 to 81 with the amino acid 83 to 218 region of the bcl-2 molecules.@ In our studies, we have shown that somatic mutation in DLL cells resulted in replacements of the amino acid at positions 29, 46, 59, and 106 of the bcl-2 protein. These structural alterations may affect interaction of bcl-2 with other bcl-2 family members and/or other oncogenes and tumor suppressor gene^.^^."^ Since the precise amino acid residues of the bcl-2 protein involved in homodimerization or heterodimerization have not been determined, the mechanism(s) by which structurally altered bcl-2 protein changes the biologic behavior of FL cells is highly speculative. The demonstration of altered amino acid residues of the bcl-2 protein in morphologically transformed FL cells shown in the present studies would contribute a first step toward the investigation of the molecular bases and pathways of lymphoma transformation.
